Elite Pharmaceuticals, Inc.
ELTP · OTC
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.04 | 0.25 | -0.03 | 13.67 |
| FCF Yield | 0.72% | 1.85% | 0.68% | -0.18% |
| EV / EBITDA | 55.55 | 7,478.75 | 23.24 | -57.60 |
| Quality | ||||
| ROIC | 8.61% | 222.62% | 10.98% | 1.38% |
| Gross Margin | 38.75% | 67.71% | 54.05% | 42.60% |
| Cash Conversion Ratio | 0.37 | -2.51 | 0.23 | 0.10 |
| Growth | ||||
| Revenue 3-Year CAGR | 44.15% | 43.81% | 35.01% | 28.25% |
| Free Cash Flow Growth | -65.65% | 360.11% | 397.45% | -177.96% |
| Safety | ||||
| Net Debt / EBITDA | -1.94 | -146.26 | -0.02 | -0.29 |
| Interest Coverage | -99.60 | 136.54 | 59.06 | 14.15 |
| Efficiency | ||||
| Inventory Turnover | 1.22 | 0.67 | 0.91 | 0.41 |
| Cash Conversion Cycle | 160.90 | 179.95 | 163.47 | 271.91 |